Sae Jung Na1, Min Ji Kang2, Dong Soo Yu2, Kyung-Do Han3, Ji Hyun Lee4, Yong Gyu Park5, Young Bok Lee6. 1. Department of Radiology, Uijeongbu St. Mary's Hospital, Seoul, Republic of Korea. 2. Department of Dermatology, Uijeongbu St. Mary's Hospital, Seoul, Republic of Korea. 3. Department of Biostatistics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 4. Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 5. Department of Biostatistics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic address: ygpark@catholic.ac.kr. 6. Department of Dermatology, Uijeongbu St. Mary's Hospital, Seoul, Republic of Korea. Electronic address: lyb80@catholic.ac.kr.
Abstract
BACKGROUND: Many studies have shown a link between inflammation and cancer development. However, there are few studies regarding the correlation between Behçet disease (BD) and cancer. OBJECTIVES: To determine the overall cancer risk and risk for specific cancers in patients with BD. METHODS: Patients with BD (n = 14,137; mean age, 44.2 ± 12.5 years; male patients, 32.4%) without known previous cancer were selected from the Korean National Health Insurance Database between 2007 and 2014. An age- and sex-matched control population of individuals without BD was randomly sampled at a ratio of 10:1. Both cohorts were followed for incident cancer until 2015. RESULTS: Overall, cancer was newly diagnosed in 451 patients with BD (3.19%) and 3975 controls (2.81%) during the follow-up period. Patients with BD showed a significantly higher risk for cancer compared with the controls (hazard ratio [HR], 1.134; 95% confidence interval [CI], 1.029-1.25), leukemia (HR, 5.801; 95% CI, 3.24-10.385), lymphoma (HR, 2.584; 95% CI, 1.559-4.283), oral cavity and pharyngeal cancer (HR, 2.113; 95% CI, 1.102-4.052), thyroid cancer (HR, 1.256; 95% CI, 1.05-1.501), and prostate cancer (HR, 1.784; 95% CI, 1.141-2.791). LIMITATIONS: The treatment or severity of diseases in each individual was not examined. CONCLUSIONS: Patients with BD had a higher risk for overall cancer compared with controls without BD. Physicians should carefully monitor patients with BD for the potential development of malignancies.
BACKGROUND: Many studies have shown a link between inflammation and cancer development. However, there are few studies regarding the correlation between Behçet disease (BD) and cancer. OBJECTIVES: To determine the overall cancer risk and risk for specific cancers in patients with BD. METHODS:Patients with BD (n = 14,137; mean age, 44.2 ± 12.5 years; male patients, 32.4%) without known previous cancer were selected from the Korean National Health Insurance Database between 2007 and 2014. An age- and sex-matched control population of individuals without BD was randomly sampled at a ratio of 10:1. Both cohorts were followed for incident cancer until 2015. RESULTS: Overall, cancer was newly diagnosed in 451 patients with BD (3.19%) and 3975 controls (2.81%) during the follow-up period. Patients with BD showed a significantly higher risk for cancer compared with the controls (hazard ratio [HR], 1.134; 95% confidence interval [CI], 1.029-1.25), leukemia (HR, 5.801; 95% CI, 3.24-10.385), lymphoma (HR, 2.584; 95% CI, 1.559-4.283), oral cavity and pharyngeal cancer (HR, 2.113; 95% CI, 1.102-4.052), thyroid cancer (HR, 1.256; 95% CI, 1.05-1.501), and prostate cancer (HR, 1.784; 95% CI, 1.141-2.791). LIMITATIONS: The treatment or severity of diseases in each individual was not examined. CONCLUSIONS:Patients with BD had a higher risk for overall cancer compared with controls without BD. Physicians should carefully monitor patients with BD for the potential development of malignancies.
Authors: Young Bok Lee; Ji Hyun Lee; Yeong Ho Kim; Ji Min Seo; Dong Soo Yu; Yong Gyu Park; Kyung Do Han Journal: Sci Rep Date: 2021-10-05 Impact factor: 4.379
Authors: Emma H Weiss; Christine J Ko; Thomas H Leung; Robert G Micheletti; Arash Mostaghimi; Sarika M Ramachandran; Misha Rosenbach; Caroline A Nelson Journal: Curr Dermatol Rep Date: 2022-03-16